Myriad Genetics Inc (MYGN)
Profitability ratios
Return on sales
| Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | |
|---|---|---|---|---|---|
| Gross profit margin | 69.89% | 68.64% | 70.22% | 71.39% | 68.01% |
| Operating profit margin | -10.51% | -34.17% | -18.23% | -7.05% | -34.97% |
| Pretax margin | -14.74% | -34.81% | -20.73% | -8.27% | -50.93% |
| Net profit margin | -15.20% | -34.96% | -16.51% | -3.94% | -40.16% |
Myriad Genetics Inc's profitability ratios paint a mixed picture of its financial performance over the years.
- The Gross Profit Margin has shown a generally positive trend, improving from 68.01% in 2020 to 71.39% in 2021, before slightly decreasing to 69.89% in 2024. This indicates that the company has been able to effectively manage its production costs and pricing strategies to generate higher profits from its sales.
- On the other hand, the Operating Profit Margin has been volatile, with negative percentages recorded in 2020 (-34.97%), 2023 (-34.17%), and 2024 (-10.51%). This suggests that the company has struggled with controlling its operating expenses relative to its revenue in those years.
- The Pretax Margin has also exhibited inconsistency, fluctuating from -50.93% in 2020 to -8.27% in 2021, before deteriorating to -14.74% in 2024. This indicates that Myriad Genetics has faced challenges in generating profits before accounting for taxes over the years.
- Lastly, the Net Profit Margin has shown improvements overall, with the company managing to reduce its net losses from -40.16% in 2020 to -3.94% in 2021, before some setbacks in subsequent years. This suggests that the company has been able to control its bottom-line performance better, although there is room for improvement.
In conclusion, while Myriad Genetics Inc has made progress in certain profitability metrics such as Gross Profit Margin and Net Profit Margin, there are ongoing challenges in terms of Operating Profit Margin and Pretax Margin. Management may need to focus on cost-cutting measures and revenue-boosting strategies to improve overall profitability.
Return on investment
| Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | |
|---|---|---|---|---|---|
| Operating return on assets (Operating ROA) | -8.56% | -22.45% | -10.32% | -3.69% | -13.73% |
| Return on assets (ROA) | -12.39% | -22.97% | -9.34% | -2.06% | -15.77% |
| Return on total capital | 0.00% | -31.66% | -13.96% | -5.03% | -22.11% |
| Return on equity (ROE) | -18.16% | -33.62% | -12.64% | -2.81% | -25.39% |
Based on the provided data, Myriad Genetics Inc's profitability ratios exhibit fluctuations over the years.
1. Operating Return on Assets (Operating ROA):
- The company's Operating ROA ranged from -22.45% in 2023 to -3.69% in 2021. This ratio indicates that the company's core operations are not generating a significant return on its assets.
2. Return on Assets (ROA):
- Myriad Genetics Inc's ROA varied from -22.97% in 2023 to -2.06% in 2021. This ratio reflects the company's overall ability to generate profit from its assets, with negative values indicating a lack of efficiency in asset utilization.
3. Return on Total Capital:
- The Return on Total Capital ranged from a negative -31.66% in 2023 to 0.00% in 2024. A negative ratio suggests that the company is not effectively utilizing its total capital to generate returns.
4. Return on Equity (ROE):
- The ROE of Myriad Genetics Inc fluctuated from -33.62% in 2023 to -2.81% in 2021. This ratio indicates how well the company is utilizing shareholder equity to generate profits, with negative values suggesting a decrease in shareholder value.
Overall, the company's profitability ratios show a mix of negative figures, indicating challenges in generating returns from its assets, total capital, and equity over the years. These trends suggest potential inefficiencies in the company's operations and financial management.